English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background The objective of this study was to characterize the  in vitro  and  in vivo  properties of the F(ab') 2  fragment of panitumumab and to investigate its potential for imaging and radioimmunotherapy. Methods The panitumumab F(ab') 2  was generated by enzymatic pepsin digestion. After the integrity and immunoreactivity of the F(ab') 2  was evaluated, the fragment was radiolabeled.  In vivo  studies included direct quantitation of tumor targeting and normal organ distribution of the radiolabeled panitumumab F(ab') 2  as well as planar γ-scintigraphy and PET imaging. Results The panitumumab F(ab') 2  was successfully produced by peptic digest. The F(ab') 2  was modified with the CHX-A"-DTPA chelate and efficiently radiolabeled with either  111 In or  86 Y.  In vivo  tumor targeting was achieved with acceptable uptake of radioactivity in the normal organs. The tumor targeting was validated by both imaging modalities with good visualization of the tumor at 24 h. Conclusions The panitumumab F(ab') 2  fragment is a promising candidate for imaging of HER1-positive cancers.

In vitro and in vivo pre-clinical analysis of a F(ab')2 fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers